

Public Health Management of Asymptomatic Close Contacts of Measles Cases



Immunization Status	2 doses, birth before 1957, or laboratory evidence of immunity or disease	1 dose	0 doses	Unknown
Risk Assessment	Presumed immunity (97% effective)	Presumed immunity for young children, and adults not at high risk (93% effective)	Susceptible	Presumed susceptible
Post-exposure Prophylaxis	If severely immunocompromised ¹ , consider IG.	MMR if >12 months old and ≥28 days from the first dose. If severely immunocompromised ¹ , consider IG.	MMR if ≥6 months old, within 3 days of initial exposure, and without contraindications. IG if <6 months old, pregnant without evidence of measles immunity, or severely immunocompromised ¹ , within 6 days of initial exposure. If ≥12 months old and ≥3 days of initial exposure, IG is not typically indicated. If 6–11 months old, IG can be administered if ≥3 days and within 6 days of initial exposure.	
Active Monitoring	None	Monitor for 21 days following last exposure (28 days if IG was administered) regardless of PEP administration. The frequency of active monitoring may be reduced for individuals who have received PEP. Health care facilities typically monitor their staff.		
Exclusion	None	<p><i>School and child care settings:</i> Exclude students unless only 1 dose recommended per vaccine schedule.</p> <p><i>Health care settings:</i> Staff can continue working, but should receive the second dose of MMR vaccine ≥28 days following the first dose.</p>	<p><i>School, child care, and healthcare settings:</i> Exclude students and staff from 5 days following first exposure through 21 days following last exposure (28 days following last exposure if IG was administered).</p> <p><i>School and child care settings:</i> At the health officer’s discretion, students and staff can be readmitted after having initiated a vaccination series for measles.</p> <p><i>Other high-risk settings:</i> Recommend voluntary quarantine for individuals.</p>	

For full recommendations and sources, refer to the [Oregon Disease Investigative Guidelines for measles](#).

¹ Severely immunocompromised patients include patients with severe primary immunodeficiency; patients who have received a bone marrow transplant until at least 12 months after finishing all immunosuppressive treatment, or longer in patients who have developed graft-versus-host disease; patients on treatment for ALL within and until at least 6 months after completion of immunosuppressive chemotherapy; and patients with a diagnosis of AIDS or HIV-infected persons with severe immunosuppression defined as CD4 percent <15% (all ages) or CD4 count <200 lymphocytes/mm³ (aged >5 years) and those who have not received MMR vaccine since receiving effective ART. (See [MMWR 2013](#) and [IDSA 2013](#)).